At the University of Maryland Medical Center, we participate in clinical research to help develop new treatment options for future patients. This involves:

  • Coordinating research protocols from large multicenter studies and principal investigator initiated studies
  • Managing multiple grants from the National Institutes of Health (NIH), the Department of Defense (DoD) and Industry Sponsors
  • Directing several current protocols engendered from the laboratory of Dr. Marc Simard M.D., Ph.D., which are now in the clinical phase, including:
    • Innovative use of Glyburide, a drug used in the treatment of diabetes, for the treatment of traumatic brain injury and ischemic stroke
    • Conduct traumatic, acute and chronic disease studies.

Here is a list of the University of Maryland's clinical research studies:

Spinal Cord Injury

NACTN

  • North American Clinical Trial Network for spinal cord injury (Registry)
  • Principal Investigator: Bizhan Aarabi, MD
  • Sponsor: Christopher and Dana Reeve Foundation

RISCIS

  • Multi-center, randomized, placebo-controlled, double-blind trial of efficacy and safety of Riluzole in acute spinal cord injury started within 12 hours of injury
  • Principal Investigator: Bizhan Aarabi, MD
  • Sponsor: AOSpine International; Christopher and Dana Reeve Foundation; Rick Hansen Institute

SPRING

  • A Phase 2b/3, Double-Blind, Randomized, Placebo Controlled, Multicenter Study to Assess the Efficacy and Safety of VX-210 in Subjects With Acute Traumatic Cervical Spinal Cord Injury
  • Principal Investigator: Bizhan Aarabi, MD
  • Sponsor: Vertex Pharmaceuticals Inc.

STRIVE

  • A phase 2b, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of Staphylococcus aureus 4-antigen vaccine (SA4Ag) in adults undergoing elective open posterior spinal fusion procedures with multilevel instrumentation
  • Principle Investigator: Charles Sansur, MD
  • Sponsor: Pfizer

Stroke

BAF312

  • A Phase II, patient and investigator-blinded, randomized, placebo-controlled study to evaluate efficacy, safety and tolerability of BAF312 in patients with stroke due to intracerebral hemorrhage (ICH)
  • Principle Investigator: E. Francois Aldrich, MD
  • Sponsor: Novartis Institutes for Biomedical Research

Movement Disorders

*To inquire about this trial at UMB, please contact Charlene Aldrich at 410-328-5332 or e-mail at caldrich@smail.umaryland.edu

ET002 MRgFUS

  • A Pivotal Study to Evaluate the Effectiveness and Safety of ExAblate Transcranial MRgFUS Thalamotomy Treatment of Medication Refractory Essential Tremor Subjects
  • Principal Investigator: Howard Eisenberg, MD
  • Sponsor: InSightec

ET002 MRgFUS CA

  • A Pivotal Study to Evaluate the Effectiveness and Safety of ExAblate Transcranial MRgFUS Thalamotomy Treatment of Medication Refractory Essential Tremor Subjects
  • Principal Investigator: Howard Eisenberg, MD
  • Sponsor: InSightec

PD002 MRgFUS

  • A Phase I Clinical Trial of the Management of the Medically-Refractory Motor Symptoms of Advanced Idiopathic Parkinson's Disease with Unilateral Lesioning of the Globus Pallidum Using the ExAblate Transcranial System
  • Principal Investigators: Howard Eisenberg, MD and Graeme Woodworth, MD
  • Sponsor: InSightec and FUS Foundation

Global Product Registry:

  • ExAblate 4000 transcranial MR guided focused ultrasound (TcMRgFUS) of Neurological Disorders
  • Principle Investigator: Howard Eisenberg, MD
  • Sponsor: InSightec

Aneurysms

NEWTON 2

  • A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Study Comparing EG-1962 to Standard of Care Oral Nimodipine in Adults with Aneurysmal Subarachnoid Hemorrhage
  • Principal Investigator: Francois Aldrich, MB, ChB, MMed, FCS
  • Sponsor: Edge Therapeutics, Inc.

Intracisternal EG-1962

  • Multicenter, Controlled, Randomized, Safety and Pharmacokinetic Study Comparing Intracisternal EG-1962 to Standard of Care Enteral Nimodipine in Adults with Aneurysmal Subarachnoid Hemorrhage
  • Principal Investigator: Francois Aldrich, MB, ChB, MMed, FCS
  • Sponsor: Edge Therapeutics, Inc.